[Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. I. Effect on cholesterol, lipid and apoprotein levels].
The effects of a new fibric acid derivative--beclobrate (Turec, Zyma) on serum lipid and apoprotein concentrations in 63 patients with primary hyperlipoproteinemia were examined. Beclobrate was given in the evening, 100 mg, once daily. After 3 months of beclobrate treatment mean total cholesterol concentration in serum decreased from 9.35 to 7.73 mmol/l (17.3%), mean LDL-cholesterol concentration from 6.32 to 5.38 mmol/l (14.9%), mean HDL-cholesterol concentration increased by 0.21 mmol/l (15.3% of initial value). The greatest decrease was observed in triglyceride concentration--by 50% of the initial value. Apoprotein B concentration decreased by 19.7%, apoprotein A1 and A2 concentration increased by 20.3% and 26.8% respectively. Higher initial values of total cholesterol and triglyceride concentration in serum were associated with greater concentration decrease after beclobrate treatment.
Sznajd
J
J
Klinika, Chorób Metabolicznych KDB AM w Krakowie.
Idzior-Waluś
B
B
Zabiński
J
J
Wybrańska
I
I
Korzus
G
G
Iwanejko
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D001059:Apoproteins / Q000097:blood*; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008875:Middle Aged
D001059:Apoproteins; D001559:Benzhydryl Compounds; D000960:Hypolipidemic Agents; D008055:Lipids; C020978:beclobrate
Beklobrat (Turec) w leczeniu pierwotnej hiperlipoproteinemii. Cześć I: Wpływ na stezenie cholesterolu, lipidy i apoproteiny.